PD-1 combined with lenvatinib and TACE for the transformational treatment of hepatocellular carcinoma combined with portal vein tumor thrombus: a case report and literature review

BACKGROUND: The prognosis of hepatocellular carcinoma combined with portal vein tumor thrombus is poor, with a median survival of only 3-6 months. PD-1 combined with targeted therapy may provide an opportunity for patients with BCLC C stage hepatocellular carcinoma combined with portal vein tumor th...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Sheng, Xiong, Rui, Duan, Chuanyi, Tang, Jiang, Yin, Tao, Dai, Sisi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586726/
https://www.ncbi.nlm.nih.gov/pubmed/37869083
http://dx.doi.org/10.3389/fonc.2023.1199143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586726/
https://www.ncbi.nlm.nih.gov/pubmed/37869083
http://dx.doi.org/10.3389/fonc.2023.1199143

Ejemplares similares